NFKB1 and inflammatory bowel disease: Treatment with non-steroidal anti-inflammatory drugs (NSAIDs) reduces the development of CRC in patients with IBD and hereditary CRC (131,132), and the inactivation of NF-κB signalling reduces the formation of inflammation-associated tumours (101,129).